Jennifer A Locke1, Gregory Russell Pond2, Guru Sonpavde3, Andrea Necchi4, Patrizia Giannatempo4, Ravi Kumar Paluri3, Guenter Niegisch5, Peter Albers5, Carlo Buonerba6, Giuseppe Di Lorenzo6, Ulka N Vaishampayan7, Scott A North8, Neeraj Agarwal9, Syed A Hussain10, Sumanta Pal11, Bernhard J Eigl12. 1. University of British Columbia, Vancouver, BC, Canada. 2. McMaster University, Hamilton, ON, Canada. 3. UAB Comprehensive Cancer Center, Birmingham, AL. 4. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Heinrich Heine University, Medical Faculty, Dusseldorf, Germany. 6. University Federico II, Naples, Italy. 7. Wayne State University Cancer Center, Detroit, MI. 8. Cross Cancer Institute, Edmonton, AB, Canada. 9. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 10. University of Liverpool, Liverpool, United Kingdom. 11. City of Hope Cancer Center, Duarte, CA. 12. British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: Bernie.Eigl@bccancer.bc.ca.
Abstract
INTRODUCTION: The optimal choice of first-line chemotherapy for patients with relapse of urothelial carcinoma (UC) after perioperative cisplatin-based chemotherapy (PCBC) is unclear. We investigated the outcomes with cisplatin rechallenge versus a non-cisplatin regimen in patients with recurrent metastatic UC after PCBC in a multicenter retrospective study. PATIENTS AND METHODS: Individual patient-level data were collected for patients who had received various first-line chemotherapy regimens for advanced UC after previous PCBC. Cox proportional hazards models were used to investigate the prognostic ability of the type of perioperative and first-line chemotherapy to independently affect overall survival (OS) and progression-free survival (PFS) after accounting for known prognostic factors. RESULTS: Data were available for 145 patients (12 centers). The mean age was 62 years; the Eastern Cooperative Oncology Group (ECOG) performance status (PS) was > 0 for 42.0% of the patients. Of the 145 patients, 63% had received cisplatin-based first-line chemotherapy. The median time from previous chemotherapy (TFPC) was 6.2 months (range, 1-154 months). The median OS was 22 months (95% confidence interval [CI], 18-27 months), and the median PFS was 6 months (95% CI, 5-7 months). A better ECOG PS and a longer TFPC (> 12 months vs. ≤ 12 months; hazard ratio [HR], 0.32; 95% CI, 0.20-0.52; P < .001) was prognostic for OS and PFS. Cisplatin-based chemotherapy was associated with poor OS (HR, 1.86; 95% CI, 1.13-3.06; P = .015), which appeared to be pronounced in those patients with a TFPC of ≤ 12 months. Retreatment with cisplatin in the first-line setting was associated with worse OS (HR, 3.38; P < .001). CONCLUSION: The results of the present retrospective analysis suggest that for patients who have undergone previous PCBC for UC, rechallenging with cisplatin might confer a poorer OS, especially for those with progression within < 1 year.
INTRODUCTION: The optimal choice of first-line chemotherapy for patients with relapse of urothelial carcinoma (UC) after perioperative cisplatin-based chemotherapy (PCBC) is unclear. We investigated the outcomes with cisplatin rechallenge versus a non-cisplatin regimen in patients with recurrent metastatic UC after PCBC in a multicenter retrospective study. PATIENTS AND METHODS: Individual patient-level data were collected for patients who had received various first-line chemotherapy regimens for advanced UC after previous PCBC. Cox proportional hazards models were used to investigate the prognostic ability of the type of perioperative and first-line chemotherapy to independently affect overall survival (OS) and progression-free survival (PFS) after accounting for known prognostic factors. RESULTS: Data were available for 145 patients (12 centers). The mean age was 62 years; the Eastern Cooperative Oncology Group (ECOG) performance status (PS) was > 0 for 42.0% of the patients. Of the 145 patients, 63% had received cisplatin-based first-line chemotherapy. The median time from previous chemotherapy (TFPC) was 6.2 months (range, 1-154 months). The median OS was 22 months (95% confidence interval [CI], 18-27 months), and the median PFS was 6 months (95% CI, 5-7 months). A better ECOG PS and a longer TFPC (> 12 months vs. ≤ 12 months; hazard ratio [HR], 0.32; 95% CI, 0.20-0.52; P < .001) was prognostic for OS and PFS. Cisplatin-based chemotherapy was associated with poor OS (HR, 1.86; 95% CI, 1.13-3.06; P = .015), which appeared to be pronounced in those patients with a TFPC of ≤ 12 months. Retreatment with cisplatin in the first-line setting was associated with worse OS (HR, 3.38; P < .001). CONCLUSION: The results of the present retrospective analysis suggest that for patients who have undergone previous PCBC for UC, rechallenging with cisplatin might confer a poorer OS, especially for those with progression within < 1 year.
Authors: C N Sternberg; P H de Mulder; J H Schornagel; C Théodore; S D Fossa; A T van Oosterom; F Witjes; M Spina; C J van Groeningen; C de Balincourt; L Collette Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: Matthew D Galsky; Sumanta K Pal; Simon Chowdhury; Lauren C Harshman; Simon J Crabb; Yu-Ning Wong; Evan Y Yu; Thomas Powles; Erin L Moshier; Sylvain Ladoire; Syed A Hussain; Neeraj Agarwal; Ulka N Vaishampayan; Federica Recine; Dominik Berthold; Andrea Necchi; Christine Theodore; Matthew I Milowsky; Joaquim Bellmunt; Jonathan E Rosenberg Journal: Cancer Date: 2015-04-14 Impact factor: 6.860
Authors: Andrea B Apolo; Irina Ostrovnaya; Susan Halabi; Alexia Iasonos; George K Philips; Jonathan E Rosenberg; Jamie Riches; Eric J Small; Matthew I Milowsky; Dean F Bajorin Journal: J Natl Cancer Inst Date: 2013-02-14 Impact factor: 13.506
Authors: C N Sternberg; A Yagoda; H I Scher; R C Watson; T Ahmed; L R Weiselberg; N Geller; P S Hollander; H W Herr; P C Sogani Journal: J Urol Date: 1985-03 Impact factor: 7.450
Authors: C N Sternberg; P de Mulder; J H Schornagel; C Theodore; S D Fossa; A T van Oosterom; J A Witjes; M Spina; C J van Groeningen; B Duclos; J T Roberts; C de Balincourt; L Collette Journal: Eur J Cancer Date: 2005-12-05 Impact factor: 9.162
Authors: P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe Journal: J Clin Oncol Date: 1992-07 Impact factor: 44.544
Authors: Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning Journal: J Clin Oncol Date: 2005-07-20 Impact factor: 44.544
Authors: Guru Sonpavde; Gregory R Pond; Ronan Fougeray; Toni K Choueiri; Angela Q Qu; David J Vaughn; Guenter Niegisch; Peter Albers; Nicholas D James; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Awais Khan; Nicholas J Vogelzang; Tomasz M Beer; Walter M Stadler; Peter H O'Donnell; Cora N Sternberg; Jonathan E Rosenberg; Joaquim Bellmunt Journal: Eur Urol Date: 2012-11-26 Impact factor: 20.096
Authors: Jung Hyun Lee; Sung Gu Kang; Seung Tae Kim; Seok Ho Kang; In Keun Choi; Young Je Park; Sang Chul Oh; Deuk Jae Sung; Jae Hong Seo; Jun Cheon; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Kyong Hwa Park Journal: Cancer Res Treat Date: 2014-04-22 Impact factor: 4.679
Authors: Andrea Necchi; Guru Sonpavde; Salvatore Lo Vullo; Daniele Giardiello; Aristotelis Bamias; Simon J Crabb; Lauren C Harshman; Joaquim Bellmunt; Ugo De Giorgi; Cora N Sternberg; Linda Cerbone; Sylvain Ladoire; Yu-Ning Wong; Evan Y Yu; Simon Chowdhury; Gunter Niegisch; Sandy Srinivas; Ulka N Vaishampayan; Sumanta K Pal; Neeraj Agarwal; Ajjai Alva; Jack Baniel; Ali-Reza Golshayan; Rafael Morales-Barrera; Daniel W Bowles; Matthew I Milowsky; Christine Theodore; Dominik R Berthold; Gedske Daugaard; Srikala S Sridhar; Thomas Powles; Jonathan E Rosenberg; Matthew D Galsky; Luigi Mariani Journal: Eur Urol Date: 2016-10-08 Impact factor: 20.096
Authors: Risa L Wong; Lorin A Ferris; Olivia A Do; Sarah K Holt; Jorge D Ramos; Simon J Crabb; Cora N Sternberg; Joaquim Bellmunt; Sylvain Ladoire; Ugo De Giorgi; Lauren C Harshman; Ulka N Vaishampayan; Andrea Necchi; Sandy Srinivas; Sumanta K Pal; Guenter Niegisch; Tanya B Dorff; Matthew D Galsky; Evan Y Yu Journal: Oncologist Date: 2021-08-17